Guidance

Reporting adverse incidents: neurostimulators

For manufacturers reporting adverse incidents with neurostimulators under the vigilance system.

From:
Medicines and Healthcare products Regulatory Agency
Published
1 June 2013
Last updated
15 January 2025 — See all updates

Documents

Device-specific vigilance guidance: neurostimulators

HTML

Details

Guidance for manufacturers on reporting adverse incidents involving stimulators under the vigilance system.

To be read in conjunction with the guidelines on post-market surveillance.

Updates to this page

Published 1 June 2013
Last updated 15 January 2025 show all updates

  1. Updated to reflect the laying of The Medical Devices (Post-market Surveillance requirements) (Amendment) Regulations 2024.

  2. This page has been updated due to the end of the transition period.

  3. First published.

Sign up for emails or print this page

Related content